NEUROFARBA Department, Section of Pharmaceutical and Nutraceutical Sciences, University of Florence, 50019 Florence, Italy.
Department of Pharmacology and Physiology, College of Osteopathic Medicine, Oklahoma State University, Tahlequah, OK 74464, USA.
Molecules. 2023 Jan 28;28(3):1270. doi: 10.3390/molecules28031270.
Positive allosteric modulators (PAMs), negative allosteric modulators (NAMs), silent agonists, allosteric activating PAMs and neutral or silent allosteric modulators are compounds capable of modulating the nicotinic receptor by interacting at allosteric modulatory sites distinct from the orthosteric sites. This survey is focused on the compounds that have been shown or have been designed to interact with nicotinic receptors as allosteric modulators of different subtypes, mainly α7 and α4β2. Minimal chemical changes can cause a different pharmacological profile, which can then lead to the design of selective modulators. Experimental evidence supports the use of allosteric modulators as therapeutic tools for neurological and non-neurological conditions.
正变构调节剂(PAMs)、负变构调节剂(NAMs)、沉默激动剂、变构激活 PAMs 和中性或沉默变构调节剂是能够通过与位于别构调节位点而非 orthosteric 位点相互作用来调节烟碱型受体的化合物。本综述重点介绍了已显示或设计为与烟碱型受体相互作用的作为不同亚型(主要是α7 和α4β2)的别构调节剂的化合物。最小的化学变化可能导致不同的药理学特征,从而导致选择性调节剂的设计。实验证据支持将变构调节剂用作治疗神经和非神经疾病的治疗工具。